Anthera Pharmaceuticals Stock EBITDA
Anthera Pharmaceuticals fundamentals help investors to digest information that contributes to Anthera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Anthera Pink Sheet. The fundamental analysis module provides a way to measure Anthera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anthera Pharmaceuticals pink sheet.
Anthera |
Anthera Pharmaceuticals Company EBITDA Analysis
Anthera Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Anthera Pharmaceuticals EBITDA | (26.59 M) |
Most of Anthera Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anthera Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Anthera Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (26.59 Million). This is 103.03% lower than that of the Biotechnology sector and 126.55% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.68% higher than that of the company.
Anthera EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anthera Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Anthera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Anthera Pharmaceuticals by comparing valuation metrics of similar companies.Anthera Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Anthera Fundamentals
| Return On Equity | -5.69 | ||||
| Return On Asset | -1.42 | ||||
| Current Valuation | (7.47 M) | ||||
| Shares Outstanding | 26.18 M | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (0.20) X | ||||
| Price To Book | 0.11 X | ||||
| Gross Profit | (28.49 M) | ||||
| EBITDA | (26.59 M) | ||||
| Net Income | (26.87 M) | ||||
| Cash And Equivalents | 8.09 M | ||||
| Cash Per Share | 0.31 X | ||||
| Debt To Equity | 1.61 % | ||||
| Current Ratio | 3.30 X | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (36.9 M) | ||||
| Short Ratio | 2.09 X | ||||
| Earnings Per Share | (1.76) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | -108.04 | ||||
| Market Capitalization | 617.83 K | ||||
| Total Asset | 3.67 M | ||||
| Retained Earnings | (436.8 M) | ||||
| Working Capital | 39.39 M | ||||
| Current Asset | 47.86 M | ||||
| Current Liabilities | 8.47 M | ||||
| Net Asset | 3.67 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Anthera Pink Sheet
If you are still planning to invest in Anthera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Anthera Pharmaceuticals' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |